Reach Us +1-217-403-9671
Nanosuspensions: An Enhanced Bioavailability Of Pulmonary Drug Delivery | 8263
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Nanosuspensions: An Enhanced Bioavailability of Pulmonary Drug Delivery

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

K. Vijaya Sri

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

I n the recent past drug discovery towards identifi cation of poorly soluble drug molecules as lead candidates has come up as the frontier area of research interest. Formation of such molecules can be challenging and demands the use of novel technologies. A number of drug delivery technologies such as solid dispersions, prodrug approach, SMEDDS, cyclodextrins, nanoparticles are the recent trends in research. As per FDA a nanoparticulate drug is not considered as generic or approved product therefore it is patentable and considered as new drug, because nanoparticulate drug is not bio-equivalent to a microcrystalline or solubilized form of the same drug, administered at the same dosage. Nano particles play a key role in increasing the saturation solubility, and consequently an increase in the dissolution rate of the compound due to small size with greater specifi c surface area. Pulmonary delivery enables local delivery of therapeutics targeting respiratory diseases such as asthma, COPD and cystic fi brosis. Th e larger pulmonary surface areas in epithelial layer, rich blood supply allows fast absorption and fast onset of drug which makes pulmonary delivery attractive for systemic delivery system. Nanosuspensions similar to nanoparticles are liquid dispersions of solid drug stabilized by polymer and or surfactant show enhanced adhesiveness to tissues. Th e tendency of the particles to stick to the mucosal surfaces at the absorption site over an extended period of time achieves an enhanced absorption rate. Th e dissolution time of nanosuspensions compared to microparticulate suspensions is increased, a prolonged residence time at the site of absorption would be still benefi cial for the uptake of anti-asthmatic drugs, as microparticles will be transported out of the lung by cilia movement, where as nanoparticle can adhere to a longer time on the mucosal surface leading to the increased e absorption of drug. Nanosuspension generally posses a very low fraction of microparticles, which reduces undesired deposition of particles in oral cavity and pharynx and decreases local and systemic side eff ects of the drug. Formulating of nanosuspensions are mainly of two types top down and bottom up technology. Th e bottom up technology involves dissolving drug in a solvent which is then added to non solvent to precipitate the crystals. Th e top down technologies include milling and high pressure homogenization

Dr.K.Vijaya Sri obtained her Ph.D from College of Pharmaceutical Sciences, Andhra University., India. She is presently working as an Associate Professor at Malla Reddy College of Pharmacy. She has published many research papers in reputed journals and her major area of research interests are poorly soluble drugs, nanosuspensions, pellets and bioanalytical techniques of drugs

Relevant Topics